About this trial
This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.
Eligibility criteria
Qualifiers
18 to 85 years of age
Diagnosis of cancer, stages I-IV
Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy)
Presence of CIPN defined as new, length-dependent numbness, tingling, and/or pain that developed with neurotoxic chemotherapy
Disqualifiers
Known brain metastases
Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN)
History of brain or spinal surgery
Neuropathy other than CIPN
Trial design
Treatments tested in this trial
- Sham Intervention
- Survey Administration
- Transcranial Direct Current Stimulation